Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03170141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03170141 · ClinicalTrials.gov record · last posted 2026-08-24

Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

StatusTerminated
PhasePhase 1
Started2017-05-31
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study aims to treat patients who have been diagnosed with brain cancer glioblastoma multiforme (GBM) including diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). The treatment combines two different approaches to fight cancer: immune modulators and antigen-specific T cells. Immune checkpoint antibodies have been tested on various tumors with good outcomes. GBM is known to express increased levels of certain antigens that can be targeted by T cells including chimeric antigen receptor-modified T (CAR-T) cells and tumor antigen specific cytotoxic lymphocytes (CTLs). In this study, the gene-modified T cells specific for GBM antigens will be combined with immune modulatory gene-modified dendritic cells (DCs) as individualized treatment regimens to treat patients.

Protocol amendment history 3 changes detected by DataLookout

2026-08-25
Trial status changed: Enrolling by Invitation → Terminated
2026-08-25
Primary completion moved earlier: 2027-07-31 → 2026-07-01
2026-08-25
Completion moved earlier: 2027-12-31 → 2026-07-31
Trial Details
NCT Number NCT03170141
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Glioblastoma Multiforme of Brain, Brain Cancer
Enrollment 30 participants
Start Date 2017-05-31
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-24